Glutamine Blocks Interleukin-13-Induced Intestinal Epithelial Barrier Dysfunction.

Area of Science:

• Gastroenterology
• Cell Biology
• Molecular Biology

Background:

• Intestinal epithelial barrier dysfunction is implicated in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
• Elevated interleukin-13 (IL-13) levels are observed in IBD patients with IBS-like symptoms.
• Glutamine supplementation has shown promise in improving gut barrier function and symptoms.

Purpose of the Study:

• To investigate the effects of IL-13 on human intestinal epithelial cells in vitro.
• To assess the potential of glutamine to counteract IL-13-induced barrier impairment.
• To elucidate the molecular mechanisms underlying these effects.

Main Methods:

• Caco-2 cells were cultured on Transwell inserts to model the intestinal epithelium.
• Transepithelial electrical resistance (TEER) and FITC-dextran permeability were measured to assess barrier function.
• Expression of tight junction proteins (claudins) was analyzed using Western blotting and immunofluorescence.

Main Results:

• IL-13 significantly reduced TEER and increased epithelial permeability.
• IL-13 altered claudin expression, decreasing claudin-1 and increasing claudin-2.
• Glutamine supplementation reversed the detrimental effects of IL-13 on barrier function and claudin expression.

Conclusions:

• IL-13 disrupts intestinal barrier integrity by downregulating claudin-1 and upregulating claudin-2.
• Glutamine alleviates IL-13-induced barrier dysfunction.
• The protective effect of glutamine involves the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway.